CytoMed Therapeutics Limited

NasdaqCM GDTC

CytoMed Therapeutics Limited Operating Income Margin for the year ending December 31, 2023: -1,002.20%

CytoMed Therapeutics Limited Operating Income Margin is -1,002.20% for the year ending December 31, 2023, a -93.17% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

CytoMed Therapeutics Limited Operating Income Margin for the year ending December 31, 2022 was -518.81%, a 69.51% change year over year.
CytoMed Therapeutics Limited Operating Income Margin for the year ending December 31, 2021 was -1,701.84%, a 19.44% change year over year.
CytoMed Therapeutics Limited Operating Income Margin for the year ending December 31, 2020 was -2,112.48%.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqCM: GDTC

CytoMed Therapeutics Limited

CEO	Mr. Chee Kong Choo
IPO Date	April 14, 2023
Location	Singapore
Headquarters	1 Commonwealth Lane, No. 08-22
Employees	28
Sector	Healthcare
Industries Biotechnology 3D Printing Robotics

Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

Key trends

Past 5 years